Results 1 to 10 of about 37,814 (299)

Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation [PDF]

Ophthalmology and Therapy, 2021
Abstract PurposeTo analyze the efficacy of biosimilar ranibizumab as compared to innovator ranibizumab and bevacizumab.MethodsWe retrospectively analyzed consecutive patients treated with biosimilar ranibizumab for wet age related macular degeneration (AMD) and macular edema (ME) and compared them with ranibizumab and bevacizumab treated ...
Dhanashree Ratra, Krishnakanta Roy, Sneha Giridhar, Sushant Madaan, Pramod Bhende, Muna Bhende, Girish Rao, Parveen Sen, Rajiv Raman, Vikas Khetan, Chetan Rao, S. Pradeep, Vinata Muralidharan, G. Suganeswari, Rupak Roy, Debmalya Das, Suchetana Mukherjee, P. S. Rajesh, V. Jayaprakash, Eesh Nigam, C. Charanya, S. Sruthi, Maitreyi Chowdhury, Kalpita Das   +23 more
openaire   +4 more sources

Ranibizumab: A Review in Retinopathy of Prematurity

Pediatric Drugs, 2021
Ranibizumab (Lucentis®) is a monoclonal antibody fragment targeted against VEGF-A that is the first approved anti-VEGF agent for the treatment of retinopathy of prematurity (ROP). In the pivotal, randomized, phase III RAINBOW trial in infants with ROP, the majority of intravitreal ranibizumab recipients experienced treatment success at 24 weeks, with a
Arnold Lee, Matt Shirley
openaire   +4 more sources

Ranibizumab and the eye [PDF]

Canadian Medical Association Journal, 2011
Ranibizumab is a recombinant, monoclonal antibody fragment that inhibits vascular endothelial growth factor (known as a VEGF-A inhibitor).1 Because it costs about 10 times more than bevacizumab,2 an anti-VEGF agent approved for intravenous use in metastatic colon cancer, ophthalmologists may ...
Jason Noble, Varun Chaudhary
openaire   +2 more sources

Mass spectrometry in ocular drug research

Mass Spectrometry Reviews, EarlyView., 2023
Abstract Mass spectrometry (MS) has been proven as an excellent tool in ocular drug research allowing analyzes from small samples and low concentrations. This review begins with a short introduction to eye physiology and ocular pharmacokinetics and the relevance of advancing ophthalmic treatments.
Eva M. del Amo, Kati‐Sisko Vellonen, Arto Urtti, Tetsuya Terasaki, Anam Hammid, Paavo Honkakoski, Seppo Auriola   +6 more
wiley   +1 more source

Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports [PDF]

, 2020
Introduction: Since vascular endothelial growth factor (VEGF) regulates several aspects of the central nervous system, particularly in dopaminergic neurons, VEGF inhibitors may be linked to Parkinson-like events and dementia, or variants of these ...
Avery, Bergvall, Caballero, Campochiaro, Cutroneo, de Jong, De Rossi, Evans, Ferrara, Ferrara, Kumar, Lim, Lindquist, McColl, Meyer, Robinson, Sanchez, Sharma, Sheikh, Simó, Steen, Storkebaum, Sultana, Thulliez, Tian, Trifirò, Ueta, Wong, Yasuhara, Ylä-Herttuala, Zachary   +30 more
core   +3 more sources

Treatment as required versus regular monthly treatment in the management of neovascular age-related macular degeneration: a systematic review and meta-analysis [PDF]

, 2015
Background: To investigate whether treatment as required ‘pro re nata’ (PRN) versus regular monthly treatment regimens lead to differences in outcomes in neovascular age-related macular degeneration (nAMD).
Agostini, Hansjuergen, Ehlken, Christoph, Loke, Yoon K., Oeller, Patrick, Rücker, Gerta, Schmucker, Christine M., Sommer, Harriet, Virgili, Gianni   +7 more
core   +11 more sources

Cost effectiveness of treatments for wet age-related macular degeneration [PDF]

, 2011
Age-related macular degeneration (AMD) is a leading cause of blindness in people aged >= 50 years. Wet AMD in particular has a major impact on patient quality of life and imposes substantial burdens on healthcare systems.
Annemans, Lieven, Gallagher, Meghan, Mitchell, Paul, Thomas, Simu, White, Richard   +4 more
core   +1 more source

Widening use of dexamethasone implant for the treatment of macular edema [PDF]

, 2017
Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis.
Avitabile T., Bonfiglio V., Fallico M., Fichera S., Longo A., Macchi I., Pizzo A., Rapisarda C., Reibaldi M., Russo A.   +9 more
core   +2 more sources

Current perspectives on ranibizumab

Clinical Ophthalmology, 2015
This review summarizes the Phase III studies addressing intravitreal ranibizumab treatment in patients with neovascular age-related macular degeneration (AMD), macular edema (ME) from retinal vein occlusion (RVO), and diabetic ME (DME).The data from 12 major Phase III studies: six studies in patients with neovascular AMD, two studies in patients with ...
Vaidehi S. Dedania, Sophie J. Bakri
openaire   +4 more sources

Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report. [PDF]

, 2018
In November 2012, a 72-year old patient was diagnosed with left eye wet age-related macular degeneration. The patient received three monthly intravitreal injections of ranibizumab, with complete resolution of retinal hemorrhage and edema and ...
Antonini, Bodis-Wollner, Brilliant, Brown, Chung, Cutroneo, de Jong, Ding, Drake, Enders, Falk, Gibson, Kemp, Krum, Miners, Naranjo, Nowacka, Nowacka, Piltonen, Pitzer, Poewe, Postuma, Pratt, Quittet, Rosenfeld, Shamloo, Sheikh, Silverman, Slotnick, Stewart, Storkebaum, Tian, Trost, Ueta, Whitton, Wu, Yasuda, Yasuhara, Yasuhara, Yasuhara, Yla-Herttuala, Yue, Zachary, Zehetner   +43 more
core   +2 more sources